Lilly Announces Acquisition of Hypnion

Deal shall bolster Lilly's Sleep Disorder Research with promising insomnia compound

07-Mar-2007

Eli Lilly and Company and Hypnion, Inc. announced that they have signed a definitive merger agreement whereby Lilly will acquire Hypnion, a privately held neuroscience drug discovery company focused on sleep disorders. The transaction has received the requisite approval of Hypnion stockholders and is expected to close near the end of the first quarter of 2007, contingent upon clearance under the Hart-Scott-Rodino Anti-Trust Improvements Act and other customary closing conditions. Financial terms of the deal were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!